elliotwaves study ERIS LIFESCIENCES

of the 5 waves corrective wave 3-4 and impulse 4-5 is pending. the final cycle in this stock can be expected to be complete by Jan2029 as it is cyclical in nature. We can confirm as long as wave 4 doesn't cross wave1.

The company is a leading player in the domestic branded formulations market. It is the youngest among the top 20 companies in the Indian Pharmaceutical Market.
The company focuses on branded generics, with 85% in chronic and 15% in acute segments. It offers drugs across various therapies, including anti-diabetes, cardiovascular, dermatology, gastroenterology, gynecology, and anti-infective